Drug Trial Radar · NCT06645522
Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Oct 30, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Yi YangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of edaravone dexborneol in treating acute ischemic stroke.
Conditions
- Acute Ischemic Stroke
Interventions
Edaravone dexborneolDrug
Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
PlaceboDrug
Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- modified rankin scale (mRS) score ≤ 1Time frame: Day 90 after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.